Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Health Information Services

10X Genomics, Inc. operates as a life science and diagnostics company. The Company develops software for analyzing biological systems such as genetic and immune cells. 10X Genomics serves customers worldwide.
Website: 10xgenomics.com



Growth: Bad revenue growth rate -2.0%, there is slowdown compared to average historical growth rates 9.0%. The revenue growth dynamics is unstable Site traffic for the last 3 months showed a change of -8.0%

Profitability: LTM EBITDA margin is negative, -9.7%. On average the margin is improving steadily. Gross margin is high, +67.3%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 40% of quarters (showing a gain of -$0.01 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 3.2% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 215.1% higher than minimum and 64.3% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 1.3x by EV / Sales multiple , the company can be 61.0% overvalued

Insiders: For the last 3 months insiders sold company shares on $0.6 mln (-0.029% of cap.)

Key Financials (Download financials)

Ticker: TXG
Share price, USD:  (0.0%)22.5
year average price 13.05  


year start price 14.47 2025-02-08

min close price 7.14 2025-04-08

max close price 23.19 2026-01-22

current price 22.50 2026-02-07
Common stocks: 113 858 684

Dividend Yield:  0.0%
EV / Sales: 3.4x
Margin (EBITDA LTM / Revenue): -9.7%
Fundamental value created in LTM:
Market Cap ($m): 2 562
Net Debt ($m): -395
EV (Enterprise Value): 2 167
Price to Book: 3.3x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-01-22prnewswire.com

10x Genomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026

2026-01-12prnewswire.com

10x Genomics Launches Study to Advance Research in Blood-Based Diagnostics for Autoimmune Disease

2026-01-12prnewswire.com

10x Genomics to Advance Research in Diagnostic Applications of Tumor Single Cell and Spatial Profiling

2025-11-06seekingalpha.com

10x Genomics, Inc. (TXG) Q3 2025 Earnings Call Transcript

2025-09-10seekingalpha.com

10x Genomics, Inc. (TXG) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

2025-08-09seekingalpha.com

10x Genomics, Inc. (TXG) Q2 2025 Earnings Call Transcript

2025-08-07zacks.com

10x Genomics (TXG) Surpasses Q2 Earnings and Revenue Estimates

2025-07-16newsfilecorp.com

Torex Gold Reports Excellent Drilling Results from EPO

2025-06-18newsfilecorp.com

Torex Gold Announces Results of Its 2025 Meeting of Shareholders

2025-06-17newsfilecorp.com

Torex Gold Resources Inc. (TXG) Closes the Market
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol TXG TXG TXG TXG TXG TXG TXG TXG TXG TXG TXG TXG TXG TXG
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-07 2025-08-08 2024-10-29 2024-08-08 2024-04-30 2023-11-03 2023-08-04 2023-05-04 2022-11-03
acceptedDate 2025-11-06 17:36:08 2025-08-07 17:40:53 2025-02-12 18:23:56 2024-10-29 16:10:00 2024-08-08 16:12:32 2024-04-30 16:11:02 2024-02-15 17:16:21 2023-11-02 19:27:55 2023-08-03 18:47:02 2023-05-04 17:04:05 2023-02-16 16:48:47 2022-11-02 20:43:58 2022-02-18 16:06:49 2021-02-26 16:10:27
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 149M 173M 611M 152M 153M 141M 619M 154M 147M 134M 516M 131M 490M 299M
costOfRevenue 49M 48M 196M 45M 46M 45M 209M 58M 47M 36M 120M 30M 74M 58M
grossProfit 100M 125M 414M 106M 107M 96M 409M 96M 100M 98M 396M 101M 416M 240M
grossProfitRatio 0.673 0.723 0.702 0.698 0.678 0.622 0.678 0.733 0.768
researchAndDevelopmentExpenses 57M 61M 265M 66M 63M 68M 270M 108M 71M 67M 266M 67M 212M 123M
generalAndAdministrativeExpenses 0 0 339M 0 0 0 0 0 0 0 295M 0 253M 200M
sellingAndMarketingExpenses 0 0 4M 0 0 0 0 0 0 0 4M 0 5M 2M
sellingGeneralAndAdministrativeExpenses 75M 74M 344M 82M 83M 85M 343M 82M 92M 83M 298M 73M 258M 202M
otherExpenses 0 -41M 0 0 -3M -2M 61M -1M -2M -2M 0 0 0 0
operatingExpenses 133M 95M 609M 148M 149M 155M 675M 190M 163M 150M 564M 141M 469M 326M
costAndExpenses 181M 143M 805M 193M 195M 200M 884M 248M 210M 186M 684M 171M 543M 384M
interestIncome 5M 4M 18M 5M 5M 5M 17M 4M 4M 4M 7M 2M 206 000 2M
interestExpense 3000 3000 4000 2000 1000 1000 33 000 1000 5000 19 000 476 000 114 000 866 000 2M
depreciationAndAmortization 12M 10M 44M 11M 11M 11M 44M 3M 12M 2M 33M 75 000 28M 19M
ebitda -16M 47M -134M -24M -26M -48M -205M -92M -61M -50M -128M -40M -25M -514M
ebitdaratio -0.107 0.27 -0.156 -0.201 -0.34 -0.597 -0.414 -0.37 -0.305
operatingIncome -32M 30M -195M -41M -42M -59M -265M -95M -63M -52M -168M -40M -53M -85M
operatingIncomeRatio -0.216 0.174 -0.274 -0.273 -0.421 -0.617 -0.432 -0.387 -0.305
totalOtherIncomeExpensesNet 4M 7M 17M 7M 5M 2M 17M -1M -2M 2M 6M -39 000 -802 000 -449M
incomeBeforeTax -28M 37M -178M -34M -37M -58M -249M -92M -61M -50M -162M -40M -54M -534M
incomeBeforeTaxRatio -0.189 0.214 -0.227 -0.242 -0.41 -0.597 -0.414 -0.37 -0.305
incomeTaxExpense -733 000 2M 5M 1M 818 000 2M 6M 1M 2M 1M 4M 2M 5M 8M
netIncome -27M 35M -183M -36M -38M -60M -255M -93M -62M -51M -166M -42M -58M -543M
netIncomeRatio -0.184 0.2 -0.236 -0.248 -0.425 -0.605 -0.425 -0.378 -0.32
eps -0.22 0.28 -1.52 -0.3 -0.32 -0.5 -2.18 -0.79 -0.53 -0.44 -1.46 -0.37 -0.53 -5.37
epsdiluted -0.22 0.28 -0.3 -0.32 -0.5 -0.79 -0.53 -0.44 -0.37
weightedAverageShsOut 126M 124M 120M 121M 120M 119M 117M 118M 117M 116M 114M 114M 110M 101M
weightedAverageShsOutDil 126M 125M 120M 121M 120M 119M 117M 118M 117M 116M 114M 114M 110M 101M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-13 2024-02-15 2023-02-16 2022-02-18 2021-02-26
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 18M 17M 6M -660 000 -150 000
ebit -178M -249M -161M -53M -533M
nonOperatingIncomeExcludingInterest -17M -17M -6M -64 000 447M
netIncomeFromContinuingOperations -183M -255M -166M -58M -543M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -183M -255M -166M -58M -543M
epsDiluted -1.52 -2.18 -1.46 -0.53 -5.37

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol TXG TXG TXG TXG TXG TXG TXG TXG TXG TXG TXG TXG TXG TXG
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-07 2025-08-08 2024-10-29 2024-08-08 2024-04-30 2023-11-03 2023-08-04 2023-05-04 2022-11-03
acceptedDate 2025-11-06 17:36:08 2025-08-07 17:40:53 2025-02-12 18:23:56 2024-10-29 16:10:00 2024-08-08 16:12:32 2024-04-30 16:11:02 2024-02-15 17:16:21 2023-11-02 19:27:55 2023-08-03 18:47:02 2023-05-04 17:04:05 2023-02-16 16:48:47 2022-11-02 20:43:58 2022-02-18 16:06:49 2021-02-26 16:10:27
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 433M 398M 344M 398M 380M 356M 359M 311M 326M 332M 220M 234M 587M 664M
shortTermInvestments 50M 50M 49M 0 269 000 16M 29M 46M 66M 86M 210M 218M 0 0
cashAndShortTermInvestments 482M 447M 393M 398M 380M 372M 389M 357M 391M 418M 430M 452M 587M 664M
netReceivables 97M 119M 88M 84M 91M 91M 115M 104M 88M 78M 104M 84M 85M 51M
inventory 62M 69M 83M 94M 88M 83M 74M 81M 84M 82M 82M 79M 60M 30M
otherCurrentAssets 19M 20M 20M 18M 20M 21M 19M 20M 19M 21M 19M 15M 1M 17M
totalCurrentAssets 660M 656M 584M 594M 579M 567M 596M 562M 583M 602M 635M 629M 748M 774M
propertyPlantEquipmentNet 296M 302M 310M 318M 324M 332M 345M 354M 356M 367M 359M 329M 230M 120M
goodwill 5M 5M 5M 5M 5M 5M 5M 5M 5M 5M 5M 5M 5M 0
intangibleAssets 65M 15M 16M 16M 17M 16M 17M 22M 22M 23M 23M 23M 25M 22M
goodwillAndIntangibleAssets 69M 19M 20M 21M 21M 21M 21M 26M 27M 27M 27M 28M 30M 22M
longTermInvestments 201 000 0 0 0 0 0 0 3M 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0 0 -3M 0 0 0 0 0 0
otherNonCurrentAssets 2M 3M 4M 5M 5M 3M 3M 6M 24M 18M 7M 10M 11M 13M
totalNonCurrentAssets 368M 324M 334M 344M 351M 356M 369M 386M 407M 412M 394M 367M 271M 155M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 1 027M 980M 919M 938M 930M 923M 965M 949M 990M 1 014M 1 029M 996M 1 019M 929M
accountPayables 18M 16M 13M 26M 21M 20M 16M 19M 23M 29M 22M 22M 17M 5M
shortTermDebt 11M 10M 0 19M 22M 11M 0 10M 9M 9M 0 8M 0 0
taxPayables 0 0 5M 4M 6M 6M 5M 4M 2M 2M 4M 3M 5M 9M
deferredRevenue 22M 21M 21M 18M 16M 14M 13M 11M 9M 9M 8M 7M 5M 6M
otherCurrentLiabilities 97M 65M 42M 54M 46M 63M 34M 65M 56M 65M 30M 90M 41M 22M
totalCurrentLiabilities 147M 112M 118M 121M 111M 109M 127M 105M 98M 112M 131M 127M 110M 118M
longTermDebt 76M 77M 0 76M 79M 81M 0 88M 90M 93M 0 88M 0 0
deferredRevenueNonCurrent 11M 11M 13M 12M 11M 10M 9M 0 0 0 3M 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 -10M 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 6M 6M 5M 5M 5M 14M 4M 10M 8M 7M 3M 57M 14M 15M
totalNonCurrentLiabilities 94M 94M 91M 94M 95M 95M 97M 99M 98M 100M 92M 94M 91M 72M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 76M 87M 83M 86M 89M 81M 95M 98M 100M 102M 95M 96M 82M 63M
totalLiabilities 241M 207M 209M 215M 206M 204M 224M 203M 196M 212M 223M 220M 201M 190M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000
retainedEarnings -1 494M -1 467M -1 467M -1 418M -1 382M -1 344M -1 284M -1 235M -1 142M -1 080M -1 029M -1 012M -863M -805M
accumulatedOtherComprehensiveIncomeLoss 138 000 220 000 -493 000 32 000 -430 000 -456 000 -429 000 -677 000 -969 000 -1M -4M -5M 22 000 -50 000
othertotalStockholdersEquity 2 279M 2 240M 2 141M 2 107M 2 064M 1 981M 1 937M 1 884M 1 793M
totalStockholdersEquity 785M 773M 710M 723M 724M 719M 741M 745M 793M 802M 806M 776M 818M 739M
totalEquity 785M 773M 710M 723M 724M 719M 741M 745M 793M 802M 806M 776M 818M 739M
totalLiabilitiesAndStockholdersEquity 1 027M 980M 938M 930M 923M 949M 990M 1 014M 996M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 1 027M 980M 919M 938M 930M 923M 965M 949M 990M 1 014M 1 029M 996M 1 019M 929M
totalInvestments 50M 50M 49M 0 269 000 16M 29M 46M 66M 86M 210M 218M 0 0
totalDebt 87M 87M 83M 86M 89M 92M 95M 98M 100M 102M 95M 96M 82M 63M
netDebt -346M -311M -261M -312M -290M -264M -264M -213M -226M -230M -125M -138M -505M -601M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-13 2024-02-15 2023-02-16 2022-02-18 2021-02-26
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 88M 115M 104M 85M 51M
otherReceivables 0 0 0 0 0
prepaids 0 0 0 14M 13M
totalPayables 18M 21M 26M 22M 13M
otherPayables 5M 5M 4M 5M 9M
accruedExpenses 28M 48M 59M 37M 71M
capitalLeaseObligationsCurrent 9M 12M 9M 5M 6M
capitalLeaseObligationsNonCurrent 73M 84M 86M 77M 57M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 2 178M 2 026M 1 839M 1 681M 1 544M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol TXG TXG TXG TXG TXG TXG TXG TXG TXG TXG TXG TXG TXG TXG
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-07 2025-08-08 2024-10-29 2024-08-08 2024-04-30 2023-11-03 2023-08-04 2023-05-04 2022-11-03
acceptedDate 2025-11-06 17:36:08 2025-08-07 17:40:53 2025-02-12 18:23:56 2024-10-29 16:10:00 2024-08-08 16:12:32 2024-04-30 16:11:02 2024-02-15 17:16:21 2023-11-02 19:27:55 2023-08-03 18:47:02 2023-05-04 17:04:05 2023-02-16 16:48:47 2022-11-02 20:43:58 2022-02-18 16:06:49 2021-02-26 16:10:27
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome -27M 35M -183M -36M -38M -60M -255M -93M -62M -51M -166M -42M -58M -543M
depreciationAndAmortization 12M 10M 44M 11M 11M 11M 44M 11M 12M 9M 33M 8M 28M 19M
deferredIncomeTax 0 0 0 0 0 0 0 -27M 3M 0 0 0 0 2M
stockBasedCompensation 25M 28M 141M 34M 38M 36M 167M 40M 46M 42M 137M 34M 96M 49M
changeInWorkingCapital 32M -54M 1M 13M -4M -6M 17M 16M -10M -6M -39M -10M -87M -50M
accountsReceivables 7M -66M 27M 8M 122 000 24M -11M -16M -10M 26M -19M -7M -34M -18M
inventory 7M 7M -10M -4M -5M -10M 8M 3M -2M -449 000 -21M -9M -30M -15M
accountsPayables 0 6M -3M 4M 1M 5M -6M -4M 2M -781 000 6M -4M 11M -8M
otherWorkingCapital 18M -858 000 -13M 5M -112 000 -24M 26M 34M -413 000 -31M -5M 10M -34M -10M
otherNonCashItems 1M -351 000 4M 64 000 64M 44M 12M 26M 463 000 2M 2M 660 000 79 000 306M
netCashProvidedByOperatingActivities 43M 18M 7M 22M 7M -16M -15M -25M -12M -4M -34M -10M -21M -218M
investmentsInPropertyPlantAndEquipment -687 000 -2M -12M -4M -4M -3M -49M -15M -25M -5M -132M -37M -101M -38M
acquisitionsNet -9M 0 0 0 0 0 0 0 0 0 -4M -2M -5M 0
purchasesOfInvestments 0 0 -49M 0 0 0 0 0 0 0 -283M -11M 0 0
salesMaturitiesOfInvestments 0 50M 30M 271 000 16M 14M 183M 20M 21M 125M 68M 17M 0 0
otherInvestingActivites 502 000 -49M 0 -1 000 000 14M 20M 0 0 0
netCashUsedForInvestingActivites -9M -939 000 -4M 12M 11M 5M -4M 120M -33M
debtRepayment 0 0 0 0 0 0 0 0 0
commonStockIssued 0 0 -6M 5M 2M 4M 0 2M 0
commonStockRepurchased 0 0 0 0 0 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 617 000 4M 156 000 5M 2M 4M 0 -6M 2M
netCashUsedProvidedByFinancingActivities 617 000 4M 156 000 5M 2M 4M 7M -3M 2M
effectOfForexChangesOnCash -33 000 360 000 -164 000 156 000 -3000 -48 000 -33 000 -85 000 -49 000 24 000 -44 000 -85 000 234 000 -463 000
netChangeInCash 35M 21M -15M 18M 24M -4M 132M -16M -9M 112M -369M -40M -93M 212M
cashAtEndOfPeriod 433M 398M 344M 398M 380M 356M 359M 312M 331M 340M 227M 242M 596M 689M
cashAtBeginningOfPeriod 398M 377M 359M 380M 356M 359M 227M 327M 340M 227M 596M 282M 689M 476M
operatingCashFlow 43M 18M 7M 22M 7M -16M -15M -25M -12M -4M -34M -10M -21M -218M
capitalExpenditure -687 000 -2M -12M -4M -4M -3M -50M -15M -25M -5M -132M -37M -101M -38M
freeCashFlow 43M 16M -6M 18M 4M -19M -65M -41M -37M -9M -165M -46M -123M -256M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-13 2024-02-15 2023-02-16 2022-02-18 2021-02-26
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities -1 000 000 -923 000 0 0 0
netCashProvidedByInvestingActivities -33M 133M -351M -107M -38M
netDebtIssuance 0 -6M -5M -5M -37M
longTermNetDebtIssuance 0 -6M -5M -5M -31M
shortTermNetDebtIssuance 0 0 0 0 -6M
netStockIssuance 11M 19M 21M 40M 482M
netCommonStockIssuance 11M 19M 21M 40M 482M
commonStockIssuance 11M 19M 21M 40M 482M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 0 0 0 0 24M
netCashProvidedByFinancingActivities 11M 14M 16M 35M 469M
incomeTaxesPaid 6M 5M 4M 9M 280 000
interestPaid 0 436 000 841 000 1M 2M

Earning call transcript

2025 q3
2025-11-06 ET (fiscal 2025 q3)
2025 q2
2025-08-09 ET (fiscal 2025 q2)
2025 q1
2025-05-08 ET (fiscal 2025 q1)
2024 q4
2025-02-12 ET (fiscal 2024 q4)
2024 q3
2024-10-29 ET (fiscal 2024 q3)
2024 q2
2024-08-08 ET (fiscal 2024 q2)
2024 q1
2024-04-30 ET (fiscal 2024 q1)
2023 q4
2024-02-15 ET (fiscal 2023 q4)
2023 q3
2023-11-02 ET (fiscal 2023 q3)
2023 q2
2023-08-03 ET (fiscal 2023 q2)
2023 q1
2023-05-03 ET (fiscal 2023 q1)
2022 q4
2023-02-15 ET (fiscal 2022 q4)
2022 q3
2022-11-02 ET (fiscal 2022 q3)
2022 q2
2022-08-08 ET (fiscal 2022 q2)
2022 q1
2022-05-04 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 8
2025-11-06 21:08 ET
10X Genomics reported for 2025 q3
SEC form 8
2025-11-06 21:08 ET
10X Genomics published news for 2025 q3
SEC form 10
2025-08-07 21:40 ET
10X Genomics reported for 2025 q2
SEC form 8
2025-08-07 20:10 ET
10X Genomics reported for 2025 q2
SEC form 8
2025-08-07 20:10 ET
10X Genomics published news for 2025 q2
SEC form 10
2025-05-09 00:00 ET
10X Genomics published news for 2025 q1
SEC form 10
2025-05-08 21:35 ET
10X Genomics published news for 2025 q1
SEC form 8
2025-05-08 20:05 ET
10X Genomics reported for 2025 q1
SEC form 8
2025-05-08 20:05 ET
10X Genomics published news for 2025 q1
SEC form 10
2025-02-13 00:00 ET
10X Genomics published news for 2024 q4
SEC form 10
2025-02-12 23:23 ET
10X Genomics published news for 2024 q4
SEC form 8
2025-02-12 16:10 ET
10X Genomics reported for 2024 q4
SEC form 8
2025-02-12 16:10 ET
10X Genomics published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
10X Genomics published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
10X Genomics published news for 2024 q4
SEC form 10
2024-10-29 16:10 ET
10X Genomics reported for 2024 q3
SEC form 8
2024-10-29 00:00 ET
10X Genomics published news for 2024 q3
SEC form 10
2024-10-29 00:00 ET
10X Genomics reported for 2024 q3
SEC form 8
2024-10-29 00:00 ET
10X Genomics reported for 2024 q3
SEC form 8
2024-10-09 00:00 ET
10X Genomics published news for 2024 q3
SEC form 8
2024-10-09 00:00 ET
10X Genomics published news for 2024 q3
SEC form 10
2024-08-08 16:12 ET
10X Genomics reported for 2024 q2
SEC form 8
2024-08-08 16:08 ET
10X Genomics published news for 2024 q2
SEC form 8
2024-08-08 16:08 ET
10X Genomics reported for 2024 q2
SEC form 8
2024-08-08 16:08 ET
10X Genomics published news for 2024 q2
SEC form 10
2024-08-08 00:00 ET
10X Genomics reported for 2024 q2
SEC form 10
2024-04-30 16:11 ET
10X Genomics published news for 2024 q1
SEC form 8
2024-04-30 16:06 ET
10X Genomics published news for 2024 q1
SEC form 8
2024-04-30 16:06 ET
10X Genomics reported for 2024 q1
SEC form 10
2024-04-30 00:00 ET
10X Genomics published news for 2024 q1
SEC form 8
2024-02-15 00:00 ET
10X Genomics published news for 2023 q4
SEC form 8
2024-02-15 00:00 ET
10X Genomics reported for 2023 q4
SEC form 10
2024-02-15 00:00 ET
10X Genomics published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
10X Genomics published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
10X Genomics published news for 2023 q4
SEC form 10
2023-11-03 00:00 ET
10X Genomics published news for 2023 q3
SEC form 10
2023-11-02 19:27 ET
10X Genomics published news for 2023 q3
SEC form 8
2023-11-02 16:05 ET
10X Genomics reported for 2023 q3
SEC form 10
2023-08-04 00:00 ET
10X Genomics published news for 2023 q2
SEC form 10
2023-08-03 18:47 ET
10X Genomics published news for 2023 q2
SEC form 6
2023-08-03 16:05 ET
10X Genomics reported for 2023 q2
SEC form 8
2023-08-03 00:00 ET
10X Genomics published news for 2023 q2
SEC form 6
2023-07-20 16:05 ET
10X Genomics published news for 2023 q2
SEC form 6
2023-06-16 16:51 ET
10X Genomics published news for 2023 q1
SEC form 10
2023-05-04 00:00 ET
10X Genomics published news for 2023 q1
SEC form 8
2023-05-03 00:00 ET
10X Genomics published news for 2023 q1
SEC form 10
2023-02-16 16:48 ET
10X Genomics reported for 2022 q4
SEC form 10
2023-02-16 00:00 ET
10X Genomics reported for 2022 q4
SEC form 6
2023-02-15 16:05 ET
10X Genomics published news for 2022 q4
SEC form 8
2023-02-15 00:00 ET
10X Genomics reported for 2022 q4
SEC form 10
2022-11-03 00:00 ET
10X Genomics reported for 2022 q3
SEC form 10
2022-11-02 20:43 ET
10X Genomics reported for 2022 q3
SEC form 6
2022-11-02 16:05 ET
10X Genomics published news for 2022 q3
SEC form 8
2022-11-02 00:00 ET
10X Genomics reported for 2022 q3
SEC form 10
2022-08-09 00:00 ET
10X Genomics reported for 2022 q2
SEC form 10
2022-08-08 19:30 ET
10X Genomics reported for 2022 q2
SEC form 6
2022-08-08 16:06 ET
10X Genomics published news for 2022 q2
SEC form 8
2022-08-08 00:00 ET
10X Genomics reported for 2022 q2
SEC form 6
2022-08-03 18:59 ET
10X Genomics published news for 2022 q2
SEC form 6
2022-08-03 17:09 ET
10X Genomics published news for 2022 q2
SEC form 6
2022-07-14 16:05 ET
10X Genomics published news for 2022 q2
SEC form 8
2022-07-14 00:00 ET
10X Genomics published news for 2022 q2
SEC form 6
2022-06-17 16:05 ET
10X Genomics published news for 2022 q1
SEC form 10
2022-05-05 16:06 ET
10X Genomics reported for 2022 q1
SEC form 10
2022-05-05 00:00 ET
10X Genomics reported for 2022 q1
SEC form 6
2022-05-04 16:06 ET
10X Genomics published news for 2022 q1
SEC form 8
2022-05-04 00:00 ET
10X Genomics reported for 2022 q1
SEC form 6
2022-04-29 16:07 ET
10X Genomics published news for 2022 q1
SEC form 10
2022-02-18 16:06 ET
10X Genomics published news for 2021 q4
SEC form 10
2022-02-18 00:00 ET
10X Genomics published news for 2021 q4
SEC form 6
2022-02-16 16:05 ET
10X Genomics published news for 2021 q4
SEC form 8
2022-02-16 00:00 ET
10X Genomics published news for 2021 q4
SEC form 10
2021-11-05 16:06 ET
10X Genomics published news for 2021 q3
SEC form 10
2021-11-05 00:00 ET
10X Genomics published news for 2021 q3
SEC form 6
2021-11-03 16:05 ET
10X Genomics published news for 2021 q3
SEC form 8
2021-11-03 00:00 ET
10X Genomics published news for 2021 q3
SEC form 10
2021-08-06 16:05 ET
10X Genomics published news for 2021 q2
SEC form 10
2021-08-06 00:00 ET
10X Genomics published news for 2021 q2
SEC form 6
2021-08-04 16:01 ET
10X Genomics published news for 2021 q2
SEC form 8
2021-08-04 00:00 ET
10X Genomics published news for 2021 q2
SEC form 6
2021-07-27 06:05 ET
10X Genomics published news for 2021 q2
SEC form 6
2021-06-15 17:01 ET
10X Genomics published news for 2021 q1
SEC form 6
2021-06-01 18:47 ET
10X Genomics published news for 2021 q1
SEC form 10
2021-05-07 16:07 ET
10X Genomics published news for 2021 q1
SEC form 10
2021-05-07 00:00 ET
10X Genomics published news for 2021 q1
SEC form 6
2021-05-05 16:07 ET
10X Genomics published news for 2021 q1
SEC form 8
2021-05-05 00:00 ET
10X Genomics published news for 2021 q1
SEC form 6
2021-04-23 16:10 ET
10X Genomics published news for 2021 q1
SEC form 6
2021-04-23 16:07 ET
10X Genomics published news for 2021 q1
SEC form 10
2021-02-26 16:10 ET
10X Genomics published news for 2020 q4
SEC form 6
2021-02-17 16:06 ET
10X Genomics published news for 2020 q4
SEC form 10
2020-11-12 16:15 ET
10X Genomics published news for 2020 q3
SEC form 6
2020-11-10 16:05 ET
10X Genomics published news for 2020 q3
SEC form 6
2020-10-13 09:21 ET
10X Genomics published news for 2020 q3
SEC form 6
2020-10-05 16:17 ET
10X Genomics published news for 2020 q3